Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 11
Submit an article Journal homepage
494
Views
20
CrossRef citations to date
0
Altmetric
Drug Evaluations

PLX4032: does it keep its promise for metastatic melanoma treatment?

Elisabeth Livingstone University Hospital Essen, Department of Dermatology, Hufelandstr 55, 45122 Essen, Germany+49 201 723 4342; +49 201 723 5935; [email protected]
, MD,
Lisa Zimmer University Hospital Essen, Department of Dermatology, Hufelandstr 55, 45122 Essen, Germany+49 201 723 4342; +49 201 723 5935; [email protected]
, MD,
Sarah Piel University Hospital Essen, Department of Dermatology, Hufelandstr 55, 45122 Essen, Germany+49 201 723 4342; +49 201 723 5935; [email protected]
, MD &
Dirk Schadendorf University Hospital Essen, Department of Dermatology, Hufelandstr 55, 45122 Essen, Germany+49 201 723 4342; +49 201 723 5935; [email protected]
, MD
Pages 1439-1449 | Published online: 14 Oct 2010

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Andrea R Hallberg, Sabine U Vorrink, Danielle R Hudachek, Kimberly Cramer-Morales, Mohammed M Milhem, Robert A Cornell & Frederick E Domann. (2014) Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma. Epigenetics 9:12, pages 1641-1647.
Read now
Robert M White. (2011) The natural history of malignancies under conditions of BRAF inhibitor stimulation. Expert Opinion on Investigational Drugs 20:1, pages 135-136.
Read now

Articles from other publishers (18)

Sungmi Jeon, Miyeon Jeon, Sanga Choi, Seongkyeong Yoo, Soohyun Park, Mingyu Lee & Iljin Kim. (2023) Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications. International Journal of Molecular Sciences 24:5, pages 4430.
Crossref
Haofan Zhang, Fengming He, Guiping Gao, Sheng Lu, Qiaochu Wei, Hongyu Hu, Zhen Wu, Meijuan Fang & Xiumin Wang. (2023) Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules 28:3, pages 943.
Crossref
Pavan Kumar Dhanyamraju, Solomon Rotimi, Priyanjali Bhattacharya & Trupti N. Patel. (2022) Revisiting the melanomagenic pathways and current therapeutic approaches. Molecular Biology Reports 49:10, pages 9651-9671.
Crossref
Changkun Hu, Yuan Huang, Peixiao Luo & Yixin Yang. (2021) Effect of antioxidants coenzyme Q10 and β‑carotene on the cytotoxicity of vemurafenib against human malignant melanoma. Oncology Letters 21:3.
Crossref
Joanna Mangana, Phil F. Cheng, Corina Kaufmann, Valerie C. Amann, Anna L. Frauchiger, Viola Stögner, Ulrike Held, Roger von Moos, Olivier Michielin, Ralph P. Braun, Mitchell P. Levesque, Simone M. Goldinger & Reinhard Dummer. (2017) Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research 27:4, pages 358-368.
Crossref
Georg Richtig, Barbara Ehall, Erika Richtig, Ariane Aigelsreiter, Tony Gutschner & Martin Pichler. (2017) Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. International Journal of Molecular Sciences 18:4, pages 715.
Crossref
James Larkin, Anthony J. Hatswell, Paul Nathan, Maximilian Lebmeier & Dawn Lee. (2015) The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLOS ONE 10:12, pages e0145524.
Crossref
J. S. Fowles, C. L. Denton & D. L. Gustafson. (2015) Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Veterinary and Comparative Oncology 13:3, pages 288-304.
Crossref
Inderjit Daphu, Sindre Horn, Daniel Stieber, Jobin Varughese, Endy Spriet, Hege Dale, Kai Skaftnesmo, Rolf Bjerkvig & Frits Thorsen. (2014) In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways. International Journal of Molecular Sciences 15:5, pages 8773-8794.
Crossref
Sahar Pakneshan, Ali Salajegheh, Robert Anthony Smith & Alfred King-Yin Lam. (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:4, pages 346-356.
Crossref
Carsten Schaefer, Lisa H. Butterfield, Sandra Lee, Grace G. Kim, Carmen Visus, Andreas Albers, John M. Kirkwood & Theresa L. Whiteside. (2012) Function but not phenotype of melanoma peptide‐specific CD8 + T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696) . International Journal of Cancer 131:4, pages 874-884.
Crossref
BARTON R. JENNINGS, MICHAEL J. MILLWARD, BENHUR AMANUEL, SIOBHAIN MULRENNAN, SIMON A. JOOSTEN & MARTIN J. PHILLIPS. (2012) Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma. Respirology 17:6, pages 991-996.
Crossref
Marcus C. Ravnan & Mazen S. Matalka. (2012) Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma. Clinical Therapeutics 34:7, pages 1474-1486.
Crossref
Vafa Shahabi, Gena Whitney, Omid Hamid, Henrik Schmidt, Scott D. Chasalow, Suresh Alaparthy & Jeffrey R. Jackson. (2012) Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunology, Immunotherapy 61:5, pages 733-737.
Crossref
Ivan Pacheco, Cristina Buzea & Victor Tron. (2011) Towards new therapeutic approaches for malignant melanoma. Expert Reviews in Molecular Medicine 13.
Crossref
Matti L. Gild, Martyn Bullock, Bruce G. Robinson & Roderick Clifton-Bligh. (2011) Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews Endocrinology 7:10, pages 617-624.
Crossref
Rieke van der Graaf & Johannes JM van Delden. (2011) Equipoise should be amended, not abandoned. Clinical Trials 8:4, pages 408-416.
Crossref
Franklin G. Miller & Steven Joffe. (2011) Equipoise and the Dilemma of Randomized Clinical Trials. New England Journal of Medicine 364:5, pages 476-480.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.